Dynavax Technologies | DVAX

Stock Price
10.06
Daily Change
0.08 0.80%
Monthly
-10.10%
Yearly
-8.79%
Q3 Forecast
9.98

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Adma Biologics 16.87 -0.04 -0.21% 3.75% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Dynavax Technologies 10.06 0.08 0.80% -8.79% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Dynavax Technologies traded at $10.06 this Friday September 5th, increasing $0.08 or 0.80 percent since the previous trading session. Looking back, over the last four weeks, Dynavax Technologies gained 10.10 percent. Over the last 12 months, its price fell by 8.79 percent. Looking ahead, we forecast Dynavax Technologies to be priced at 9.98 by the end of this quarter and at 9.73 in one year, according to Trading Economics global macro models projections and analysts expectations.

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing novel vaccines. The Company's products include HEPLISAV-B and CpG 1018TM. The HEPLISAV-B is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The Company also manufactures and sells CpG 1018TM, the adjuvant used in HEPLISAV-B. The Company also engaged in developing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.